Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.

Arbyn M, de Sanjosé S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL, Denny L, Bornstein J, Abramowitz L, Giuliano A, Tommasino M, Monsonego J.

Int J Cancer. 2012 Nov 1;131(9):1969-82. doi: 10.1002/ijc.27650. Review.

2.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; Authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012..

Vaccine. 2013 Nov 22;31 Suppl 8:I1-31. doi: 10.1016/j.vaccine.2013.07.026. Review.

3.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012..

Vaccine. 2013 Dec 29;31 Suppl 5:F1-31. doi: 10.1016/j.vaccine.2013.10.001. Review.

PMID:
24331745
4.

Burden of human papillomavirus infection and related diseases in Israel.

Shavit O, Roura E, Barchana M, Diaz M, Bornstein J.

Vaccine. 2013 Nov 22;31 Suppl 8:I32-41. doi: 10.1016/j.vaccine.2013.05.108. Review.

PMID:
24229717
5.

Global burden of human papillomavirus and related diseases.

Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S.

Vaccine. 2012 Nov 20;30 Suppl 5:F12-23. doi: 10.1016/j.vaccine.2012.07.055. Review.

PMID:
23199955
6.

HPV and HPV-associated diseases.

Dunne EF, Park IU.

Infect Dis Clin North Am. 2013 Dec;27(4):765-78. doi: 10.1016/j.idc.2013.09.001. Review.

PMID:
24275269
7.

Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.

Toh ZQ, Licciardi PV, Fong J, Garland SM, Tabrizi SN, Russell FM, Mulholland EK.

Vaccine. 2015 Sep 22;33(39):5042-50. doi: 10.1016/j.vaccine.2015.07.102. Review.

PMID:
26271829
8.

The burden of human papillomavirus infections and related diseases in sub-saharan Africa.

De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, Denny L, Parham GP.

Vaccine. 2013 Dec 29;31 Suppl 5:F32-46. doi: 10.1016/j.vaccine.2012.07.092. Review.

9.

HPV in genital cancers (at the exception of cervical cancer) and anal cancers.

de Sanjosé S, Bruni L, Alemany L.

Presse Med. 2014 Dec;43(12 Pt 2):e423-8. doi: 10.1016/j.lpm.2014.10.001. Review.

PMID:
25455637
10.

A review of clinical trials of human papillomavirus prophylactic vaccines.

Schiller JT, Castellsagué X, Garland SM.

Vaccine. 2012 Nov 20;30 Suppl 5:F123-38. doi: 10.1016/j.vaccine.2012.04.108. Review.

11.

Human papillomavirus-related disease in men: not just a women's issue.

Palefsky JM.

J Adolesc Health. 2010 Apr;46(4 Suppl):S12-9. doi: 10.1016/j.jadohealth.2010.01.010. Review. Erratum in: J Adolesc Health. 2010 Jun;46(6):614.

12.

[The disease burden of human papillomavirus in men is substantial and can potentially be prevented].

Kiellberg Larsen H, Kofoed K, Sand C.

Ugeskr Laeger. 2013 Feb 4;175(6):349-53. Review. Danish.

PMID:
23402241
13.

HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.

Gillison ML, Chaturvedi AK, Lowy DR.

Cancer. 2008 Nov 15;113(10 Suppl):3036-46. doi: 10.1002/cncr.23764. Review.

15.
16.

Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.

Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Muñoz N, Schiffman M, Bosch FX.

Vaccine. 2008 Aug 19;26 Suppl 10:K17-28. doi: 10.1016/j.vaccine.2008.06.021. Review.

17.

Human papillomavirus vaccines and adolescents.

Kahn JA, Bernstein DI.

Curr Opin Obstet Gynecol. 2005 Oct;17(5):476-82. Review.

PMID:
16141761
18.

Human papillomavirus: science and technologies for the elimination of cervical cancer.

Bosch FX.

Expert Opin Pharmacother. 2011 Oct;12(14):2189-204. doi: 10.1517/14656566.2011.596527. Review.

PMID:
21756205
19.

A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.

Goldstone SE, Vuocolo S.

Expert Rev Vaccines. 2012 Apr;11(4):395-406. doi: 10.1586/erv.12.20. Review.

PMID:
22551023
20.

EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection.

Giuliano AR, Nyitray AG, Kreimer AR, Pierce Campbell CM, Goodman MT, Sudenga SL, Monsonego J, Franceschi S.

Int J Cancer. 2015 Jun 15;136(12):2752-60. doi: 10.1002/ijc.29082. Review.

Items per page

Supplemental Content

Support Center